We are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.

DC Investment Partners

HBM Healthcare Investments AG

Adage Capital Management

RA Capital Management

Longwood Fund

MPM Capital

Soleus Capital

Sphera Global Healthcare Fund

Taiho Ventures

UPMC Enterprises

Werewolf Therapeutics

We are excited to share preliminary monotherapy data from our WTX-124 Phase 1/1b clinical trial at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. https://bit.ly/45SOV8Y #ImmunoOncology #Cytokines #SITC2023 #HOWL

Excited to be at SITC in San Diego to present 6 posters sharing Wereowlf’s exciting advancement and data!

We’re #hiring a new Accountant in Watertown, Massachusetts. Apply today or share this post with your network.

Werewolf will be @ SITC and would welcome discussions with investors and partners. Reach out to me! See you in San Diego.

We are looking forward to the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. Be sure to visit our six poster presentations, including interim first-in-human clinical data from our WTX-124 Phase 1/1b study. Learn More: https://lnkd.in/gjjR58w3
#ImmunoOncology #Cytokines #SITC2023 $HOWL

On Sunday 9/24 we are honored to recognize #WorldCancerResearchDay and raise awareness for #cancerresearch. At Werewolf we remain committed to transforming cancer treatment through innovation. Learn more here https://werewolftx.com/

Moonlight Therapeutics is a biopharmaceutical company specializing in innovative immuno-oncology therapeutics.

Moonlight Therapeutics

Nightshade Biotech is a healthcare company focused on developing cutting-edge immuno-oncology treatments and therapies.

Nightshade Biotech

Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company's proprietary PREDATOR platform designs conditionally activated molecules that stimulate adaptive and innate immunity to address the limitations of conventional proinflammatory immune therapies.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Werewolf Therapeutics, Inc.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom	Mar 8, 2024 9:13 AM	7fd363c0
news impact assignment basic	general	Mar 8, 2024 9:13 AM	1edc21b2
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 9:13 AM	c6cd33db
company summary	general
signals	general	Mar 8, 2024 9:13 AM	a0ed6554
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Mar 8, 2024 9:13 AM	3b182ce4
news basic	general	Mar 8, 2024 9:13 AM	22d669c5
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:WEREWOLFTX

Werewolf Therapeutics, Inc.

Last Close

2.74

26/07 20:00

Market Cap

95.60M

Beta: -

Volume Today

163.49K

Avg: -